Capecitabine
Intestinal Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical SciencesSmall moleculePhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Intestinal Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Pfizer | Phase 3 | BB |
FLUOROURACILUM Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | BB |
Eloxatin Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | BB |
SIMVASTATIN University of Auckland, New Zealand | Phase 3 | BB |
pf-08634404 Pfizer | Phase 3 | B |
View all 13 →
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →